James Harper joins Cornerstone's board
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics, a specialty pharmaceutical company focused on acquiring, developing and commercialising products for the hospital and respiratory markets, has appointed James Harper to its board of directors. Mr Harper is currently chair of Phenomix Corporation and an advisor to Nomura Phase4 Ventures. Prior to his retirement, he held a number of management and senior executive positions at Lilly.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.